Validity of an atopic dermatitis outcome measure for real-world clinical practice

Christina Topham
Oregon Health & Science University

Dylan Haynes
Oregon Health & Science University

Molly Brazil
Oregon Health & Science University

Eric Simpson
Oregon Health & Science University

Follow this and additional works at: https://pdxscholar.library.pdx.edu/publichealthpdx

Part of the Dermatology Commons, Other Public Health Commons, and the Skin and Connective Tissue Diseases Commons

Let us know how access to this document benefits you.

Topham, Christina; Haynes, Dylan; Brazil, Molly; and Simpson, Eric, "Validity of an atopic dermatitis outcome measure for real-world clinical practice" (2019). OHSU-PSU School of Public Health Annual Conference. 17.
https://pdxscholar.library.pdx.edu/publichealthpdx/2019/Posters/17

This Poster is brought to you for free and open access. It has been accepted for inclusion in OHSU-PSU School of Public Health Annual Conference by an authorized administrator of PDX Scholar. For more information, please contact pdxscholar@pdx.edu.
Validity of an atopic dermatitis outcome measure for real-world clinical practice

Topham C; Haynes D; Brazil M; Simpson EL

Oregon Health & Science University, Department of Dermatology

Introduction: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the United States. AD is associated with reduced quality of life and substantial financial costs, making it burdensome at an individual and population level. Disease severity outcome measures are validated tools to assess severity and therapeutic response. Recent consensus statements have identified gold-standard outcome measures for AD in clinical trials, but further work is needed evaluating outcome measures feasible for clinical practice.

Objective: To investigate the validity and feasibility of the product of investigator global assessment and body surface area (IGA x BSA) as an outcome measure for AD in the clinical setting.

Methods and Results: Retrospective chart review of patients with AD seen in an outpatient dermatology clinic at Oregon Health & Science University from 2015-2018 with recorded BSA and IGA revealed 246 patients comprising 682 clinic visits. We observed strong and statistically significant correlations between IGA x BSA and the gold-standard measurement for clinical signs in clinical trials, the Eczema Area and Severity Index ($r=0.9105, p <0.0001, n=19$). IGA x BSA also showed strong correlations with the average daily pruritus numerical rating scale ($r=0.7108, p <0.0001, n=177$) and the patient global assessment ($r=0.7389, p <0.0001, n=170$).

Conclusions: IGA x BSA is a valid and feasible outcome measure for AD which aligns with patient-reported disease severity and may be used in real-world clinical practice.